Oncogenic osteomalacia: Diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT SCAN for the diagnosis and follow-up in one case

Bone

Volumn 36, Issue 3, 2005, Pages 375-378

  Dupond, J L ^a   Mahammedi, H ^a   Prie D ^b   Collin, F ^c   Gil, H ^a   Blagosklonov, O ^a   Ricbourg, B ^a   Meaux Ruault, N ^a   Kantelip, B ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b BICHAT HOSPITAL   (France)

^c Georges Francois Leclerc Center   (France)

Author keywords

F 18 FDG PET SCAN; FGF23; Hypophosphatemia; Oncogenic osteomalacia; Phosphatonins; Phosphaturic mesenchymal tumors

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111;

AGED; ARTICLE; BONE PAIN; BONE SCINTISCANNING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; HYPOPHOSPHATEMIA; MALE; MANDIBLE TUMOR; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; POSITRON EMISSION TOMOGRAPHY; RADIODENSITOMETRY; TUMOR LOCALIZATION;

EID: 15544385175     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.01.001     Document Type: Article

References (24)

1. A.L. Folpe, J.C. Fanburg-Smith, S.D. Billings, M. Bisceglia, F. Bertoni, J.Y. Cho, and M.J. Econs Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive reviews of the literature Am. Surg. Pathol. 28 2004 1 30
2. S.C. Schiavi, and R. Kumar The phosphatonin pathway: new insights in phosphate homeostasis Kidney Int. 65 2004 1 14
3. T.O. Carpenter Oncogenic osteomalacia. A complex dance of factors N. Engl. J. Med. 348 2003 1705 1708
4. K.B. Jonsson, R. Zahradnik, T. Larsson, K.E. White, T. Sugimoto, and Y. Imahishy Fibroblast growth factor in oncogenic osteomalacia and X-linked hypophosphatemia N. Engl. J. Med. 348 2003 1656 1663
5. T. Shimada, S. Mizutani, T. Muto, T. Yoneya, R. Hino, and S. Takeda Cloning and characterisation of FGF23 as a causative factor of tumor-induced osteomalacia Proc. Natl. Acad. Sci. U. S. A. 98 2001 6500 6505
6. T.J. Weber, S. Liu, O. Indridason, and L.D. Quarles Serum FGF23 levels in normal and disordered phosphorus homeostasis J. Bone Miner. Res. 18 2003 1227 1234
7. 111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia Clin. Nucl. Med. 24 1999 130 131
8. 111IN- pentetreotide total body scan Clin. Exp. Rheumatol. 21 2003 493 496
9. T. Beyer, G. Antoch, S. Muller, T. Egelhof, L.S. Freudenberg, and J. Debatin Acquisition protocol considerations for combined PET/CT imaging J. Nucl. Med. 45 Suppl 1 2004 25S 35S
10. A.C. Koeger, A. Prier, P.H. Vinceneux, and J.P. Camus Les ostéomalacies tumorales hypophosphorémiques Presse Med. 14 1985 1747 1751
11. Y.K. Park, K.K. Unni, J.W. Beabout, and J.F. Hodgson Oncogenic osteomalacia. A clinicopathological study of 17 bone lesions J. Korean Med. Sci. 9 1994 289 298
12. D. Weiss, R.S. Bar, N. Weidner, M. Wener, and F. Lee Oncogenic osteomalacia: strange tumor in strange places Post-Grad. Med. J. 61 1985 349 355
13. M.K. Drezner Tumor-induced osteomalacia M.J. Favus Primer on the metabolic bone diseases and disorders of mineral metabolism 4th edition 1999 Lippicott William and Wilkins Philadelphia 331 337
14. N. Weidner, and D. Santa Cruz Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets Cancer 59 1987 1442 1454
15. T. Berndt, T.A. Craig, A.E. Bowe, J. Vassiliadis, D. Reczek, and R. Finnegan Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent J. Clin. Invest. 112 2003 785 794
16. P.S.N. Rowe, Y. Kumagai, G. Gutierrez, I.R. Garret, R. Blacher, and D. Rosen MEPE has the properties of an osteoblastic phosphatonin and minhibin Bone 34 2004 303 319
17. K.E. White, K.B. Jonsson, G. Carn, G. Hampson, T.D. Spector, and M. Mannstadt The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting J. Clin. Endocrinol. Metab. 86 2001 497 500
18. L.M. Ward, F. Raunch, K.E. White, G. Filler, M.A. Matzinger, and M. Letts Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF23-producing tumor of the distal ulna Bone 34 2004 905 911
19. Y. Yamazaki, R. Okazaki, M. Shibata, Y. Hasegawa, K. Satoh, and T. Tajima Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphoremic rickets-osteomalacia J. Clin. Endocrinol. Metab. 87 2002 4957 4960
20. T. Shimida, T. Muto, T. Urukawa, T. Yoneya, Y. Yamazaki, and K. Okawa Mutant FGF23 responsible for autosomal dominant hypophosphatemia is resistant to proteolytic cleavage and causes hypophosphatemia in vivo Endocrinology 143 2002 3179 3182
21. T. Larsson, U. Nisbeth, O. Ljunggren, H. Juppner, and K.B. Jonsson Circulating concentration of FGF23 increases as renal function declines in patients with chronic kidney diseases, but does not change in response to variation in phosphate intake in healthy volunteers Kidney Int. 64 2003 2272 2279
22. T.J. Eber, S. Lii, O.S. Indridason, and L.D. Quarles Serum FGF23 levels in normal and disordered phosphorus homeostasis J. Bone Miner. Res. 18 2003 1227 1234
23. J. Seufert, K. Ebert, J. Muller, J. Eulert, C. Hendrich, and E. Werner Octreotide therapy for tumor-induced osteomalacia N. Engl. J. Med. 345 2001 1883 1888
24. Y.L. Rhee, J.D. Lee, H.C. Shin, K.B. Huh, and S.K. Lim Oncogenic osteomalacia associated with mesenchymal tumor detected by indium-111 octreotide scintigraphy Clin. Endocrinol. 54 2001 551 554